Ponatinib (iclusig) 30MG tab item # 63020-0533-300
Ended Awarded Last action
- Contract number
- 36C26022F0200
- Awardee
-
Takeda Pharmaceuticals America, Inc. UEI ENNFDLWFC6L1 Part of Takeda Pharmaceutical Company LIMITED
- Awarding agency
-
Veterans Integrated Service Network 20
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $160,406
Award facts
- Contract value 100% obligated
- $160,406.28 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Cambridge, MA 02139, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$213,875 | |
| Funding Only Action | $213,875 | |
| Original award | $160,406 |
About this award
This is a delivery order awarded by the Department of Veterans Affairs Veterans Health Administration to Takeda Pharmaceuticals America, Inc., a foreign-owned, for-profit manufacturer of pharmaceutical products. The order is for the oncology medication ponatinib (ICLUSIG) 30mg tablets, with a potential value of $160,406.28. The contract was placed against Takeda's GSA Schedule 61-IB for Pharmaceuticals and Drugs, utilizing a firm-fixed price pricing structure. The order has an estimated completion date of April 28, 2023 and was awarded on April 29, 2022. No set-aside designation was used. Takeda Pharmaceuticals America, as a subsidiary of the global biopharmaceutical company Takeda Pharmaceutical Company Limited, has a history of providing specialty pharmaceutical products to the VA through prime and subcontract awards, including other oncology medications like ixazomib (NINLARO). This delivery order is part of a larger VA National Acquisition Center blanket purchase agreement with Takeda that has a potential value exceeding $13 million for ICLUSIG products.
Quick answers
Who was awarded contract 36C26022F0200?
36C26022F0200 was awarded to Takeda Pharmaceuticals America, Inc. by Veterans Integrated Service Network 20 (Veterans Health Administration) on April 29, 2022.
How much is contract 36C26022F0200 worth?
The government has obligated $160,406 on 36C26022F0200.
Is contract 36C26022F0200 an order under another contract?
Yes. 36C26022F0200 is a delivery order under 36F79718D0586, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26022F0200 competed?
The extent of competition for 36C26022F0200 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award